MIMCIPAR 30MG TABLET contains Cinacalcet which belongs to a group of medicines called Calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. It is used for secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis and for hypercalcemia in patients with parathyroid outgrowth.
Hyperparathyroidism (HPT) is a condition where the parathyroid gland may become overactive and make too much PTH. In this condition the calcium stored in the bones move into the blood leading to hypercalcemia (too much calcium in the blood). Secondary hyperparathyroidism (SHPT) describes an alteration in bone and mineral metabolism that occurs as a direct result of chronic kidney disease (CKD). The parathyroid gland is the central organ responsible for regulating these adaptive responses leading to secondary hyperparathyroidism. Parathyroid hormone helps in low calcium levels by acting on the bones, intestine, and kidneys. MIMCIPAR 30MG TABLET works by controlling levels of the parathyroid hormone (PTH), calcium and phosphorous in body.
Do not drive or operate machines, if you experience side effects such as dizziness and seizures while taking this medicine. If you are pregnant or breast-feeding, think you may be pregnant or planning to have a baby, ask your doctor for advice before taking this medicine. The most common side effects are nausea, vomiting, dizziness, rash, muscle pain, loss of appetite, headache. Consult your doctor if you experience any of the above side effects persists for a longer duration.
No content available
